Eden BioSolutions plc (AIM: EDEN), the UK-listed biopesticide specialist, has announced that the United States Environmental Protection Agency has granted unconditional registration under FIFRA for Mevalone Delta, an optimised biofungicide formulation built on the company's Sustaine® microencapsulation technology. The approval covers a broad range of fungal diseases across high-value crops whose combined US farm-gate value reached approximately $33 billion in 2024. Eden estimates the total addressable market for Mevalone Delta in the US at around $144 million, representing a material commercial opportunity for the AIM-listed company and its US distribution partner, Sipcam Agro USA.

Key Points

  • Eden BioSolutions plc (AIM: EDEN) — UK-listed biopesticide and biocontrol technology company
  • US EPA has granted unconditional FIFRA registration for Mevalone Delta, an enhanced biofungicide formulation
  • Covered crops had a combined US farm-gate value of approximately $33 billion in 2024; total addressable US market estimated at $144 million
  • Investors should watch for state-level registrations, expected to take between one and twelve months, and subsequent commercial sales updates from Sipcam

Mevalone Delta Label Covers Grapes, Almonds, Strawberries and Key Fungal Diseases Worth $33 Billion at the Farm Gate

The approved EPA label permits Mevalone Delta to target grey mould (Botrytis cinerea), powdery mildew, Sclerotinia, brown rot blossom blight (Monilinia) and chocolate spot (Botrytis fabae) across crops including grapes, almonds, strawberries and leafy vegetables. Based on USDA data cited in the announcement, grapes alone accounted for approximately $6.2 billion in US farm-gate value in 2024, almonds $5.7 billion, leafy vegetables $5.5 billion, and strawberries $4.0 billion. The label also permits application up to three days before harvest, giving growers late-season flexibility that the company highlights as commercially significant for high-value fruit and vegetable producers.

Sustaine® Microencapsulation and Naturally Derived Active Ingredients Underpin Mevalone Delta's Resistance Management Profile

Mevalone Delta shares its three naturally derived active ingredients with Eden's existing Mevalone® product — eugenol, geraniol and thymol — and is classified by the Fungicide Resistance Action Committee as a Group BM01 fungicide with multiple modes of action. This classification makes it compatible with integrated pest management programmes and positions it as a tool to delay or prevent resistance to single-site fungicides. The announcement states the optimised formulation is designed to compete in more cost-sensitive market segments while maintaining efficacy, potentially broadening the product's commercial reach compared with the original Mevalone formulation.

Sipcam Agro USA to Distribute Mevalone Delta as State-Level Registrations Progress Over the Next Twelve Months

Mevalone Delta will be distributed in the United States by Sipcam Agro USA, Eden's existing commercial partner for the original Mevalone product. Following the federal EPA registration, the product must now obtain individual state-level registrations before it can be sold or distributed in each state, a process the announcement states is expected to take between one and twelve months depending on the jurisdiction. Eden estimates it could achieve a market share of around 3% at the point of peak sales within the $144 million total addressable US market, though the timeline to that milestone was not disclosed in the announcement.

Eden's $144 Million US Market Estimate Rests on Grower Demand for Biological Crop Protection Alternatives

A key sector driver cited in the announcement is mounting pressure on growers of high-value US crops from retailers, export markets and regulators to reduce chemical pesticide residues, supporting demand for effective biological alternatives. Eden derives 100% of its annual revenues from sustainable products and holds the London Stock Exchange Green Economy Mark. A company-specific risk is the dependence on state-by-state regulatory approvals and on the commercial execution of its single US distribution partner, Sipcam, before Mevalone Delta can generate meaningful US revenues. Investors may be watching state registration progress and initial sales data from Sipcam as near-term indicators.